SBFMW SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)
- 0.205
- -0.010-4.70%
S-3: Registration statement for specified transactions by certain issuers
8-K: Current report
SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(0.00%),Steven Boyd(0.00%)
424B4: Prospectus
EFFECT: Others
8-K: SUNSHINE BIOPHARMA REPORTS 2024 THIRD QUARTER RESULTS: YEAR-TO-DATE REVENUES UP 54%
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
10-Q: Q3 2024 Earnings Report
8-K: Current report
DEF 14A: Definitive information statements
8-K: Current report
10-Q/A: Quarterly report (Amendment)
8-K: SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER RESULTS: SECOND QTR REVENUES UP 67%, YTD REVENUES UP 61%
10-Q: Q2 2024 Earnings Report
NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
8-K: Current report
DEF 14C: Definitive information statements
8-K: Current report
PRE 14C: Preliminary information statement not related to a contested matter or merger/acquisition
8-K: Current report